Cargando…
Decoys Selection in Benchmarking Datasets: Overview and Perspectives
Virtual Screening (VS) is designed to prospectively help identifying potential hits, i.e., compounds capable of interacting with a given target and potentially modulate its activity, out of large compound collections. Among the variety of methodologies, it is crucial to select the protocol that is t...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787549/ https://www.ncbi.nlm.nih.gov/pubmed/29416509 http://dx.doi.org/10.3389/fphar.2018.00011 |
_version_ | 1783295954713051136 |
---|---|
author | Réau, Manon Langenfeld, Florent Zagury, Jean-François Lagarde, Nathalie Montes, Matthieu |
author_facet | Réau, Manon Langenfeld, Florent Zagury, Jean-François Lagarde, Nathalie Montes, Matthieu |
author_sort | Réau, Manon |
collection | PubMed |
description | Virtual Screening (VS) is designed to prospectively help identifying potential hits, i.e., compounds capable of interacting with a given target and potentially modulate its activity, out of large compound collections. Among the variety of methodologies, it is crucial to select the protocol that is the most adapted to the query/target system under study and that yields the most reliable output. To this aim, the performance of VS methods is commonly evaluated and compared by computing their ability to retrieve active compounds in benchmarking datasets. The benchmarking datasets contain a subset of known active compounds together with a subset of decoys, i.e., assumed non-active molecules. The composition of both the active and the decoy compounds subsets is critical to limit the biases in the evaluation of the VS methods. In this review, we focus on the selection of decoy compounds that has considerably changed over the years, from randomly selected compounds to highly customized or experimentally validated negative compounds. We first outline the evolution of decoys selection in benchmarking databases as well as current benchmarking databases that tend to minimize the introduction of biases, and secondly, we propose recommendations for the selection and the design of benchmarking datasets. |
format | Online Article Text |
id | pubmed-5787549 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-57875492018-02-07 Decoys Selection in Benchmarking Datasets: Overview and Perspectives Réau, Manon Langenfeld, Florent Zagury, Jean-François Lagarde, Nathalie Montes, Matthieu Front Pharmacol Pharmacology Virtual Screening (VS) is designed to prospectively help identifying potential hits, i.e., compounds capable of interacting with a given target and potentially modulate its activity, out of large compound collections. Among the variety of methodologies, it is crucial to select the protocol that is the most adapted to the query/target system under study and that yields the most reliable output. To this aim, the performance of VS methods is commonly evaluated and compared by computing their ability to retrieve active compounds in benchmarking datasets. The benchmarking datasets contain a subset of known active compounds together with a subset of decoys, i.e., assumed non-active molecules. The composition of both the active and the decoy compounds subsets is critical to limit the biases in the evaluation of the VS methods. In this review, we focus on the selection of decoy compounds that has considerably changed over the years, from randomly selected compounds to highly customized or experimentally validated negative compounds. We first outline the evolution of decoys selection in benchmarking databases as well as current benchmarking databases that tend to minimize the introduction of biases, and secondly, we propose recommendations for the selection and the design of benchmarking datasets. Frontiers Media S.A. 2018-01-24 /pmc/articles/PMC5787549/ /pubmed/29416509 http://dx.doi.org/10.3389/fphar.2018.00011 Text en Copyright © 2018 Réau, Langenfeld, Zagury, Lagarde and Montes. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Réau, Manon Langenfeld, Florent Zagury, Jean-François Lagarde, Nathalie Montes, Matthieu Decoys Selection in Benchmarking Datasets: Overview and Perspectives |
title | Decoys Selection in Benchmarking Datasets: Overview and Perspectives |
title_full | Decoys Selection in Benchmarking Datasets: Overview and Perspectives |
title_fullStr | Decoys Selection in Benchmarking Datasets: Overview and Perspectives |
title_full_unstemmed | Decoys Selection in Benchmarking Datasets: Overview and Perspectives |
title_short | Decoys Selection in Benchmarking Datasets: Overview and Perspectives |
title_sort | decoys selection in benchmarking datasets: overview and perspectives |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787549/ https://www.ncbi.nlm.nih.gov/pubmed/29416509 http://dx.doi.org/10.3389/fphar.2018.00011 |
work_keys_str_mv | AT reaumanon decoysselectioninbenchmarkingdatasetsoverviewandperspectives AT langenfeldflorent decoysselectioninbenchmarkingdatasetsoverviewandperspectives AT zaguryjeanfrancois decoysselectioninbenchmarkingdatasetsoverviewandperspectives AT lagardenathalie decoysselectioninbenchmarkingdatasetsoverviewandperspectives AT montesmatthieu decoysselectioninbenchmarkingdatasetsoverviewandperspectives |